Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)”

3 trials

Showing 3 of 3 results

Large-scale testing (Phase 3)Looking for participantsNCT06123884
What this trial is testing

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Who this might be right for
Cervical Cancer
Bio-Thera Solutions 526
Testing effectiveness (Phase 2)UnknownNCT05075122
What this trial is testing

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Martin-Luther-Universität Halle-Wittenberg 75
Large-scale testing (Phase 3)UnknownNCT05715840
What this trial is testing

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Who this might be right for
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 368

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation